Current Environment: Production

Medical Services

Specialties

Programs & Services

Education

Undergraduate School

Princeton University

1990, Princeton, NJ

Medical School

Mt. Sinai School of Medicine

1994, New York, NY

Residency

Pediatrics

Yale-New Haven Children's Hospital

1998, New Haven, CT

Fellowship

Memorial Sloan-Kettering Cancer Center

2001, New York, NY

Fellowship

New York University Medical Center

2002, New York, NY

Publications

  1. Correction to: Cancer survivorship programs at the Dana-Farber Cancer Institute. J Cancer Surviv. 2025 Jun; 19(3):1112. View Abstract

  2. Cellular hierarchies of embryonal tumors with multilayered rosettes are shaped by oncogenic microRNAs and receptor-ligand interactions. Nat Cancer. 2025 May 26. View Abstract

  3. Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial. Nat Med. 2025 Apr 16. View Abstract

  4. SMARCB1 missense mutants disrupt SWI/SNF complex stability and remodeling activity. Res Sq. 2025 Mar 26. View Abstract

  5. Treatment Approach for Metastatic Intracranial Germinoma: A Multi-Institutional Experience. Pediatr Blood Cancer. 2025 May; 72(5):e31628. View Abstract

  6. Pediatric Central Nervous System Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025 Mar; 23(3):113-130. View Abstract

  7. Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trial. Neuro Oncol. 2024 Dec 19. View Abstract

  8. Author Correction: Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer. Nat Commun. 2024 Aug 22; 15(1):7218. View Abstract

  9. Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer. Nat Commun. 2024 Jul 11; 15(1):5837. View Abstract

  10. Clinical utility of DNA methylation profiling for choroid plexus tumors. Neurooncol Adv. 2024 Jan-Dec; 6(1):vdae097. View Abstract

  11. Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial. Nat Med. 2024 May; 30(5):1500. View Abstract

  12. Off-label prescribing of immune checkpoint inhibitor therapy at a single pediatric cancer center. Cancer Med. 2024 Apr; 13(8):e7154. View Abstract

  13. Cancer survivorship programs at the Dana-Farber Cancer Institute. J Cancer Surviv. 2024 02; 18(1):34-41. View Abstract

  14. A Pilot Study Omitting Radiation in the Treatment of Children with Newly Diagnosed Wnt-Activated Medulloblastoma. Clin Cancer Res. 2023 12 15; 29(24):5031-5037. View Abstract

  15. Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen: A Nonrandomized Controlled Trial. JAMA Oncol. 2023 12 01; 9(12):1688-1695. View Abstract

  16. The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial. Nat Med. 2024 Jan; 30(1):207-217. View Abstract

  17. Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C. J Natl Cancer Inst. 2023 11 08; 115(11):1355-1363. View Abstract

  18. ALK Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma. Clin Cancer Res. 2023 07 14; 29(14):2651-2667. View Abstract

  19. Recent progress and novel approaches to treating atypical teratoid rhabdoid tumor. Neoplasia. 2023 03; 37:100880. View Abstract

  20. Current advances in immunotherapy for atypical teratoid rhabdoid tumor (ATRT). Neurooncol Pract. 2023 Aug; 10(4):322-334. View Abstract

  21. p53 Pathway Inactivation Drives SMARCB1-deficient p53-wildtype Epithelioid Sarcoma Onset Indicating Therapeutic Vulnerability Through MDM2 Inhibition. Mol Cancer Ther. 2022 11 03; 21(11):1689-1700. View Abstract

  22. Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma. Neuro Oncol. 2022 11 02; 24(11):1964-1975. View Abstract

  23. PD-L1 and PD-1 expression in pediatric central nervous system germ cell tumors. Mod Pathol. 2022 12; 35(12):1770-1774. View Abstract

  24. An international study evaluating the epidemiology of intracranial germ cell tumors in the native versus immigrant Japanese populations: the need for an international registry. J Neurooncol. 2022 Sep; 159(3):563-570. View Abstract

  25. Structural variants shape driver combinations and outcomes in pediatric high-grade glioma. Nat Cancer. 2022 08; 3(8):994-1011. View Abstract

  26. Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma. J Clin Invest. 2022 Jun 15; 132(12). View Abstract

  27. DICER1 mutations in primary central nervous system tumors: new insights into histologies, mutations, and prognosis. J Neurooncol. 2022 May; 157(3):499-510. View Abstract

  28. Pearls & Oy-sters: Pivoting Treatment Regimens of Pediatric Atypical Teratoid Rhabdoid Tumors to Optimize Care in Adult ATRT: A Case Report. Neurology. 2022 04 26; 98(17):726-730. View Abstract

  29. Comparison of toxicity following single versus tandem autologous transplant regimens for pediatric medulloblastoma. Pediatr Transplant. 2022 06; 26(4):e14229. View Abstract

  30. The challenges in treating embryonal tumors with multilayered rosettes (ETMR) and other infant brain tumors. Neuro Oncol. 2022 01 05; 24(1):138-140. View Abstract

  31. Multi-institutional analysis of treatment modalities in basal ganglia and thalamic germinoma. Pediatr Blood Cancer. 2021 10; 68(10):e29172. View Abstract

  32. Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma of childhood: Report of a COG randomized Phase II screening trial. Pediatr Blood Cancer. 2021 08; 68(8):e29031. View Abstract

  33. Retrospective evaluation of single patient investigational new drug (IND) requests in pediatric oncology. Cancer Med. 2021 Apr; 10(7):2310-2318. View Abstract

  34. Outcomes after first relapse of childhood intracranial ependymoma. Pediatr Blood Cancer. 2021 08; 68(8):e28930. View Abstract

  35. Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma. J Clin Invest. 2020 12 01; 130(12):6325-6337. View Abstract

  36. A POETIC Phase II study of continuous oral everolimus in recurrent, radiographically progressive pediatric low-grade glioma. Pediatr Blood Cancer. 2021 02; 68(2):e28787. View Abstract

  37. A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study. Neuro Oncol. 2020 10 14; 22(10):1527-1535. View Abstract

  38. A modified IRS-III chemotherapy regimen leads to prolonged survival in children with embryonal tumor with multilayer rosettes. Neurooncol Adv. 2020 Jan-Dec; 2(1):vdaa120. View Abstract

  39. Trametinib for the treatment of recurrent/progressive pediatric low-grade glioma. J Neurooncol. 2020 Sep; 149(2):253-262. View Abstract

  40. Advancing biology-based therapeutic approaches for atypical teratoid rhabdoid tumors. Neuro Oncol. 2020 07 07; 22(7):944-954. View Abstract

  41. Immune checkpoint inhibition for pediatric patients with recurrent/refractory CNS tumors: a single institution experience. J Neurooncol. 2020 Aug; 149(1):113-122. View Abstract

  42. Mechanisms and therapeutic implications of hypermutation in gliomas. Nature. 2020 04; 580(7804):517-523. View Abstract

  43. Genomic and Immunologic Characterization of INI1-Deficient Pediatric Cancers. Clin Cancer Res. 2020 06 15; 26(12):2882-2890. View Abstract

  44. Increasing value of autopsies in patients with brain tumors in the molecular era. J Neurooncol. 2019 Nov; 145(2):349-355. View Abstract

  45. Revisiting the Role of Radiation Therapy for Pediatric Low-Grade Glioma. J Clin Oncol. 2019 12 10; 37(35):3335-3339. View Abstract

  46. Neuro-Oncology Practice Clinical Debate: targeted therapy vs conventional chemotherapy in pediatric low-grade glioma. Neurooncol Pract. 2020 Jan; 7(1):4-10. View Abstract

  47. Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations. Neuro Oncol. 2019 08 05; 21(8):968-980. View Abstract

  48. A Central Role of Radiation Therapy in Central Nervous System Germinoma. Int J Radiat Oncol Biol Phys. 2019 08 01; 104(5):970-971. View Abstract

  49. Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma. Neuro Oncol. 2019 03 18; 21(4):537-546. View Abstract

  50. Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition. Elife. 2019 03 12; 8. View Abstract

  51. Cutaneous reactions to targeted therapies in children with CNS tumors: A cross-sectional study. Pediatr Blood Cancer. 2019 06; 66(6):e27682. View Abstract

  52. Improvement of hereditary palmoplantar keratoderma with oral trametinib. Pediatr Dermatol. 2019 Jan; 36(1):e48-e49. View Abstract

  53. Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma. Neuro Oncol. 2018 10 09; 20(11):1547-1555. View Abstract

  54. A phase 1/2 dose-finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous system. Pediatr Blood Cancer. 2018 09; 65(9):e27217. View Abstract

  55. Rethinking childhood ependymoma: a retrospective, multi-center analysis reveals poor long-term overall survival. J Neurooncol. 2017 Oct; 135(1):201-211. View Abstract

  56. Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. Neuro Oncol. 2017 Jul 01; 19(7):986-996. View Abstract

  57. A pediatric trial of radiation/cetuximab followed by irinotecan/cetuximab in newly diagnosed diffuse pontine gliomas and high-grade astrocytomas: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study. Pediatr Blood Cancer. 2017 Nov; 64(11). View Abstract

  58. A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors. Clin Cancer Res. 2017 May 15; 23(10):2433-2441. View Abstract

  59. Long-term neuropsychological follow-up of young children with medulloblastoma treated with sequential high-dose chemotherapy and irradiation sparing approach. J Neurooncol. 2017 05; 133(1):119-128. View Abstract

  60. Pediatric oncology enters an era of precision medicine. Curr Probl Cancer. 2017 May - Jun; 41(3):194-200. View Abstract

  61. Pediatric malignant germ cell tumors: A comparison of the neuro-oncology and solid tumor experience. Pediatr Blood Cancer. 2016 12; 63(12):2086-2095. View Abstract

  62. Central Versus Extraventricular Neurocytoma in Children: A Clinicopathologic Comparison and Review of the Literature. J Pediatr Hematol Oncol. 2016 08; 38(6):479-85. View Abstract

  63. Clinical, Pathological, and Molecular Characterization of Infant Medulloblastomas Treated with Sequential High-Dose Chemotherapy. Pediatr Blood Cancer. 2016 09; 63(9):1527-34. View Abstract

  64. Disseminated glioneuronal tumors occurring in childhood: treatment outcomes and BRAF alterations including V600E mutation. J Neurooncol. 2016 06; 128(2):293-302. View Abstract

  65. Building a new process: Nursing verification of pediatric oral chemotherapy. J Clin Oncol. 2016 Mar; 34(7_suppl):199. View Abstract

  66. Atypical teratoid/rhabdoid tumors-current concepts, advances in biology, and potential future therapies. Neuro Oncol. 2016 06; 18(6):764-78. View Abstract

  67. Myxopapillary ependymomas in children: imaging, treatment and outcomes. J Neurooncol. 2016 Jan; 126(1):165-174. View Abstract

  68. Classification of treatment-related mortality in children with cancer: a systematic assessment. Lancet Oncol. 2015 Dec; 16(16):e604-10. View Abstract

  69. A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors. Childs Nerv Syst. 2015 Sep; 31(9):1433-45. View Abstract

  70. Rhabdoid tumors: integrating biological insights with clinical success: a report from the SMARCB1 and Rhabdoid Tumor Symposium, Paris, December 12-14, 2013. Cancer Genet. 2014 Sep; 207(9):346-51. View Abstract

  71. Recurrence after gross-total resection of low-grade pediatric brain tumors: the frequency and timing of postoperative imaging. J Neurosurg Pediatr. 2014 Oct; 14(4):356-64. View Abstract

  72. Phase I individual dose titration trial of the human corticotropin-releasing factor (hcrf), corticorelin acetate injection (xerecept) in pediatric patients with peritumoral edema of the brain. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii23. View Abstract

  73. Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: an analysis of the Surveillance Epidemiology and End Results (SEER) database. Pediatr Blood Cancer. 2014 Jul; 61(7):1173-9. View Abstract

  74. A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. Pediatr Blood Cancer. 2014 Apr; 61(4):636-42. View Abstract

  75. Predictors of neoplastic disease in children with isolated pituitary stalk thickening. Pediatr Blood Cancer. 2013 Oct; 60(10):1630-5. View Abstract

  76. Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR- ErbB2 signaling with lapatinib. Mol Oncol. 2013 Jun; 7(3):497-512. View Abstract

  77. Absence of oncogenic canonical pathway mutations in aggressive pediatric rhabdoid tumors. Pediatr Blood Cancer. 2012 Dec 15; 59(7):1155-7. View Abstract

  78. Sleep dysfunction in long term survivors of craniopharyngioma. J Neurooncol. 2012 Jul; 108(3):543-9. View Abstract

  79. Brain tumors in children. Curr Probl Pediatr Adolesc Health Care. 2012 Apr; 42(4):80-103. View Abstract

  80. Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J Clin Oncol. 2011 Oct 20; 29(30):3999-4006. View Abstract

  81. Prospective collection of tissue samples at autopsy in children with diffuse intrinsic pontine glioma. Cancer. 2010 Oct 01; 116(19):4632-7. View Abstract

  82. Germinoma with malignant transformation to nongerminomatous germ cell tumor. J Neurosurg Pediatr. 2010 Sep; 6(3):295-8. View Abstract

  83. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. J Clin Oncol. 2010 Jun 20; 28(18):3069-75. View Abstract

  84. Biological modification strategies following marrow ablative, high-dose chemotherapy (HDCT) with autologous hematopoietic stem cell rescue (AHSCR) for pediatric brain tumors. Pediatr Blood Cancer. 2010 Apr; 54(4):654-6. View Abstract

  85. Introduction to a special issue on pediatric neuro-oncology. J Child Neurol. 2009 Nov; 24(11):1341-2. View Abstract

  86. A prospective, blinded analysis of A-PROTEIN (recoverin or CAR protein) levels in pediatric patients with central nervous system tumors. Pediatr Blood Cancer. 2009 Sep; 53(3):343-7. View Abstract

  87. Medical, psychological, cognitive and educational late-effects in pediatric low-grade glioma survivors treated with surgery only. Pediatr Blood Cancer. 2009 Sep; 53(3):417-23. View Abstract

  88. Pediatric Neuro-Oncology: Back to the Basics. 2009.

  89. Tumors of the Brain and Spinal Cord. Oncology of Infancy and Childhood (Orkin, Fisher, Look, Lux, Ginsbrug, Nathan, eds). 2009; 601-720.

  90. Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol. 2009 Jan 20; 27(3):385-9. View Abstract

  91. Prognostic value of tumor microinvasion and metalloproteinases expression in intracranial pediatric ependymomas. J Neuropathol Exp Neurol. 2008 Sep; 67(9):911-20. View Abstract

  92. Outcome of pediatric pineoblastoma after surgery, radiation and chemotherapy. J Neurooncol. 2008 Aug; 89(1):89-95. View Abstract

  93. Results from a single-arm, multi-institutional Phase II study Of multi-agent intrathecal and systemic Cchemotherapy with age- and risk-adapted radiation therapy for children with newly diagnosed CNS Atypical Teratoid/Rhabdoid Tumor. Neuro-oncol. 2008; 10(3):373.

  94. Long-term medical, psychologicak and educational isues in pediatric low-grade gliomas treated with surgery only. Neuro-Oncol. 2007.

  95. Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue. Pediatr Blood Cancer. 2007 Jul; 49(1):34-40. View Abstract

  96. Moyamoya following cranial irradiation for primary brain tumors in children. Neurology. 2007 Mar 20; 68(12):932-8. View Abstract

  97. Newly diagnosed high-risk malignant brain tumors with leptomeningeal dissemination in young children: a final update on “Head Start” induction chemotherapy intensified with high-dose methotrexate. Proceedings of ASCO. 2007.

  98. Pineoblastoma in the pediatric population: Review of a single institution’s experience. Neuro-Oncol. 2007; 9:201.

  99. Glomerular filtration rate in comparison to serum creatinine and audiologic results in predicting toxicity in pediatric patients receiving vincristine and carboplatin. Neuro-Oncol. 2007; 9:175.

  100. Does histologic grade correlate with clinical outcome in pediatric intracranial ependymoma?. Neuro-Oncol. 2007; 9:217.

  101. Supratentorial primitive neuroectodermal tumors: Final outcome for children enrolled on Head Start I and II. Neuro-Oncol. 2007; 9:192.

  102. Oligodendroglial lineage marker expression in ependymal tumors. Neuro-Oncol. 2007; 9:218.

  103. Phase II study of thalidomide and radiation in children with newly diagnosed brain stem gliomas and glioblastoma multiforme. J Neurooncol. 2007 Mar; 82(1):95-101. View Abstract

  104. Transverse myelitis after therapy for primitive neuroectodermal tumors. Pediatr Neurol. 2006 Aug; 35(2):122-5. View Abstract

  105. A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol. 2005 Nov; 27(11):573-81. View Abstract

  106. Continuous remission of newly diagnosed and relapsed central nervous system atypical teratoid/rhabdoid tumor. J Neurooncol. 2005 Mar; 72(1):77-84. View Abstract

  107. Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma. J Clin Oncol. 2004 Dec 15; 22(24):4881-7. View Abstract

  108. The patterns of relapse in osteosarcoma: the Memorial Sloan-Kettering experience. Pediatr Blood Cancer. 2004 Jan; 42(1):46-51. View Abstract

  109. Pediatric Neuro-Oncology Program Fellows Manual. 2004.

  110. Expression of SSX-2 and SSX-4 genes in neuroblastoma. Int J Biol Markers. 2002 Oct-Dec; 17(4):219-23. View Abstract

  111. Neuroblastic and Schwannian stromal cells of neuroblastoma are derived from a tumoral progenitor cell. Cancer Res. 2001 Sep 15; 61(18):6892-8. View Abstract

  112. Prognostic significance of GAGE detection in bone marrows on survival of patients with metastatic neuroblastoma. Med Pediatr Oncol. 2000 Dec; 35(6):632-4. View Abstract
BESbswy